真实临床实践中的体重减轻与反弹:TARGET-NASH观察队列结果
Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-01-21
本研究基于TARGET-NASH观察队列,评估非酒精性脂肪性肝病(NAFLD)患者体重减轻的发生率及可持续性,并识别相关因素。原文指出体重减轻≥5%可减少肝脂肪变,≥10%与肝脏炎症和纤维化改善相关。
要点
- NAFLD一线治疗聚焦生活方式减重,≥5%减重可减少肝脂肪变。
- ≥10%减重与肝脏炎症和纤维化改善相关。
- 研究评估NAFLD患者减重发生率、可持续性及相关因素。
核心结论
- 研究评估了NAFLD患者体重减轻的发生率和可持续性,并识别相关因素。
研究设计与样本
- 基于TARGET-NASH观察队列的分析。
关键数值与推荐
- 体重减轻≥5%可减少肝脂肪变;体重减轻≥10%与肝脏炎症和纤维化改善相关。
临床怎么用
- NAFLD一线治疗应聚焦通过生活方式调整实现体重减轻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
First-line treatment for nonalcoholic fatty liver disease (NAFLD) focuses on weight loss through lifestyle modifications.1,2 Weight loss ≥5% results in reduction of steatosis and weight loss ≥10% has been associated with improvement in hepatic inflammation and fibrosis.3 The incidence and sustainability of weight loss among patients with NAFLD were estimated and associating factors identified.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Malespin MH, Barritt AS, Watkins SE, et al. Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clin Gastroenterol Hepatol. 2021. PMID: 33486083. doi:10.1016/j.cgh.2021.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。